Figure 1. Trial enrollment details.
A total of 67 healthy volunteers were assessed for eligibility based on inclusion/exclusion criteria (see Supplemental Methods for complete list). A total of 29 subjects were randomized for the cross-over study (canagliflozin vs. placebo [BPO]). Four subjects withdrew from the study after randomization. Therefore, data were collected and analyses performed on 25 subjects.